Drug Trial Radar · NCT03398135
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,242
Actual
Start
Aug 28, 2018
Primary completion
Sep 2028
Study completion Feb 2029
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jan 12, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC. This study consists of three sub-studies and a Continuous Treatment Extension (CTE): Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic or due to the geopolitical conflict in Ukraine and surrounding impacted regions. The CTE is an open-label extension for Substudy 3 completers to ensure continuous treatment with risankizumab until such time that risankizumab becomes commercially available and/or the subject can access treatment locally.
Conditions
- Ulcerative Colitis (UC)
Interventions
risankizumabDrug
subcutaneous (SC) injection
placebo for risankizumabDrug
subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Adapted Mayo ScoreTime frame: Week 52
- Percentage of Participants with Adverse Events (AE)Time frame: Up to Week 300
Locations
426 sites in 43 countries. Site status is shown where the registry gives one.
Southern California Res. Ctr. /ID# 169659
Coronado, California
Hoag Memorial Hosp Presbyterian /ID# 218347
Irvine, California
UC San Diego Health System /ID# 160430
La Jolla, California
United Medical Doctors /ID# 158574
Los Alamitos, California
Cedars-Sinai Medical Center /ID# 163848
Los Angeles, California
Gastrointestinal Biosciences Clinical Trials, LLC /ID# 200934
Los Angeles, California
UCSF Medical Center - Mount Zion /ID# 201209
San Francisco, California
Peak Gastroenterology Associates, PC /ID# 165838
Colorado Springs, Colorado
Rocky Mountain Pediatric Gastroenterology /ID# 207173
Lone Tree, Colorado
Duplicate_Medical Research Center of CT /ID# 160287
Hamden, Connecticut
Yale Univ Digestive Diseases /ID# 213265
New Haven, Connecticut
South Lake Pain Institute, Inc /ID# 162859
Clermont, Florida
Ctr for Advanced Gastroenterol /ID# 202820
Maitland, Florida
University of Miami /ID# 160456
Miami, Florida
Coral Research Clinic /ID# 158608
Miami, Florida
South Florida Research Ph I-IV, Inc. /ID# 161844
Miami, Florida
Gastroenterology Group Naples /ID# 165210
Naples, Florida
Advanced Research Institute, Inc /ID# 161945
New Port Richey, Florida
Advent Health /ID# 160393
Orlando, Florida
Endoscopic Research, Inc. /ID# 206709
Orlando, Florida
Omega Research Group /ID# 203105
Orlando, Florida
Duplicate_Lenus Research & Medical Group /ID# 169727
Sweetwater, Florida
Clinical Research Trials of Florida, Inc. /ID# 201794
Tampa, Florida
Duplicate_AdventHealth Tampa /ID# 170482
Tampa, Florida
Gastroenterology Associates of Central Georgia, LLC /ID# 160513
Macon, Georgia
The University of Chicago Medical Center /ID# 160511
Chicago, Illinois
DM Clinical Research/Southwest /ID# 165009
Oak Lawn, Illinois
Indiana University /ID# 167250
Indianapolis, Indiana
Univ Kansas Med Ctr /ID# 226601
Kansas City, Kansas
Cotton O'Neil Clinical Research Center, Digestive Health /ID# 160367
Topeka, Kansas
Duplicate_Robley Rex VA Medical Center /ID# 218647
Louisville, Kentucky
Houma Digestive Health Special /ID# 158377
Houma, Louisiana
Delricht Research /ID# 206817
New Orleans, Louisiana
Nola Research Works, LLC /ID# 161356
New Orleans, Louisiana
Louisiana Research Center, LLC /ID# 201205
Shreveport, Louisiana
Massachusetts General Hospital - Crohn's and Colitis Center /ID# 164257
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 159430
Ann Arbor, Michigan
Clin Res Inst of Michigan, LLC /ID# 160300
Chesterfield, Michigan
Mayo Clinic - Rochester /ID# 200455
Rochester, Minnesota
Quality Clinical Research Inc. /ID# 167312
Omaha, Nebraska
Showing 40 of 426 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.